title: Long-term biochemical and virological response to natural interferon-alpha in patients with chronic hepatitis C.
abstract: To determine the long-term response to interferon-alpha, 134 patients with chronic hepatitis C were followed for more than a year after therapy. Follow-up was stopped for 14 patients and 43 patients received retreatment. The remaining 77 patients were followed for 26-46 months, and 39 of them achieved long-term sustained alanine aminotransferase (ALT) normality. This normality was achieved in 35/38 short-term sustained responders, which was significantly higher (P < 0.001) than in the short-term relapsers (2/38) and the short-term nonresponders (2/44). Hepatitis C virus (HCV) RNA remained negative in 27 (73%) of 37 patients in the long-term sustained ALT normality group. However, only one (1.6%) of 63 long-term responders was negative for HCV RNA. The results of HCV RNA testing for the long-term period agreed with those at three to six months after therapy. Serum ALT levels during the first six months after therapy and HCV RNA testing at three to six months after therapy are important for predicting long-term sustained ALT normality and HCV RNA negativity.
authors.affiliation: First Department of Medicine, Osaka University School of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Hagiwara
authors.forename: N
authors.initials: N
authors.lastname: Hayashi
authors.forename: A
authors.initials: A
authors.lastname: Kasahara
authors.forename: M
authors.initials: M
authors.lastname: Oshita
authors.forename: K
authors.initials: K
authors.lastname: Katayama
authors.forename: M
authors.initials: M
authors.lastname: Naito
authors.forename: M
authors.initials: M
authors.lastname: Masuzawa
authors.forename: H
authors.initials: H
authors.lastname: Yoshihara
authors.forename: Y
authors.initials: Y
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Fusamoto
authors.forename: T
authors.initials: T
authors.lastname: Kamada
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000097:blood / Q000628:therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors
chemical_list: D015415:Biomarkers; D016898:Interferon-alpha; D012367:RNA, Viral; D000410:Alanine Transaminase